Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis.

Ricardo da Cruz LageClaudia Diniz Lopes MarquesThauana Luiza OliveiraGustavo Gomes ResendeCharles Lubianca KohemCarla Gonçalves SaadAntônio Carlos XimenesCélio Roberto GonçalvesWashington Alves BianchiEduardo de Souza MeirellesMauro Waldemar KeisermanAdriano ChiereghinCristiano Barbosa CampanholoAndré Marun LyrioCláudia Goldenstein SchainbergLenise Brandao PieruccettiMichel Alexandre YazbekPenelope Esther PalominosRafaela Silva Guimarães GoncalvesRodrigo Luppino AssadRubens BonfiglioliSônia Maria Alvarenga Anti Loduca LimaSueli CarneiroValderílio Feijó AzevedoCleandro Pires AlbuquerqueWanderley Marques BernardoPercival Degrava Sampaio-BarrosMarcelo de Medeiros Pinheiro
Published in: Advances in rheumatology (London, England) (2021)
Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians' decision making, without taking out his/her autonomy when prescribing for an individual patient.